Diabetes: assessing the pipeline

Atherosclerosis. Supplements
Harold Lebovitz

Abstract

Type 2 diabetes is recognised as a major cardiovascular risk factor, and future therapies must therefore address more than just blood glucose levels. Novel approaches to the treatment of type 2 diabetes are now at various stages of development or regulatory approval. Exenatide and pramlintide, analogues of gut-derived hormones glucagon-like peptide-1 (GLP-1) and amylin, respectively, have demonstrated improvements in glycaemic control and bodyweight in clinical studies and have been recently approved for treatment of type 2 diabetes. Initial studies have indicated that agents that activate both peroxisome proliferator-activated receptor (PPAR)alpha and gamma improve glycaemic control and have beneficial effects on lipid profiles. Two dual PPARalpha/gamma agonists, muraglitazar and tesaglitazar, are under regulatory review and in phase III trials, respectively. Modulation of the endogenous endocannabinoid system by rimonabant, which is under regulatory review, has been shown to improve body weight, atherogenic lipid profiles and glycaemic control. In addition, enhanced understanding of the pathophysiology underlying the microvascular complications of type 2 diabetes has led to the development of targeted therapies for conditions...Continue Reading

References

Aug 1, 1986·The Journal of Clinical Endocrinology and Metabolism·M A NauckW Creutzfeldt
Feb 13, 2001·Endocrinology·D J Drucker
Nov 8, 2001·Trends in Pharmacological Sciences·E Schlicker, M Kathmann
Aug 14, 2002·Annals of Medicine·Michael Stumvoll, Hans-Ulrich Häring
Oct 27, 2004·Diabetes Care·John B BuseUNKNOWN Exenatide-113 Clinical Study Group
Nov 25, 2004·Diabetes·Ole SchmitzJorgen Rungby
May 6, 2005·Journal of the American Society of Nephrology : JASN·Katherine R Tuttle
May 11, 2005·Scientific American·Alan E Rubin
Oct 19, 2005·Annals of Internal Medicine·Robert J HeineUNKNOWN GWAA Study Group
Oct 22, 2005·JAMA : the Journal of the American Medical Association·Steven E NissenEric J Topol
Mar 21, 2006·Clinical Cornerstone·Lawrence Blonde

❮ Previous
Next ❯

Citations

Mar 29, 2008·Metabolic Syndrome and Related Disorders·Andrew J Krentz
Sep 13, 2011·PLoS Computational Biology·Yvonne Y LiSteven J M Jones
Nov 6, 2009·International Journal of Epidemiology·Lindsay McLarenSharon Kirkpatrick
Jun 30, 2007·Nature Reviews. Drug Discovery·Menelas N PangalosOrest Hurko
Jan 5, 2008·Current Diabetes Reports·Jennifer B Green, Mark N Feinglos
Oct 13, 2006·Journal of Medicinal Chemistry·Neeraj MahindrooHsing-Pang Hsieh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.